News|Slideshows|November 6, 2020

Top 5 Seizure and Epilepsy Apps for Primary Care

A first aid guide for caregivers, an app that allows patients to track epilepsy trends, and 3 more top epilepsy and seizure apps for primary care.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

October 21st, 2026

Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

October 7th, 2026

FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke

FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.

October 6th, 2026

9 Drugs Approved for Primary Care: Q3 2026

Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

September 25th, 2026

Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades

Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.

October 20th, 2026

Insulin Resistance May Partly Explain Higher Cardiovascular Risk After Premature Menopause

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.

October 20th, 2026

Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms

TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.

October 20th, 2026

AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026

In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.

October 19th, 2026

Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A

Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and promise for primary care triage to endoscopy.

Top 5 Seizure and Epilepsy Apps for Primary Care

Related to this article

Trending on Patient Care Online

Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A

Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms

Insulin Resistance May Partly Explain Higher Cardiovascular Risk After Premature Menopause

AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026

Long-Acting Injectable HIV PrEP: Efficacy, Safety, and Injection Reactions